

Nephrologist Virtual
Consultation for
Finerenone Initiation
(NIHB patients)

Finerenone (Kerendia) is a non-steroidal mineralocorticoid receptor antagonist indicated to lower the risk of **CKD** progression associated with **Type 2 Diabetes**.

- *NIHB provides coverage for Finerenone after consultation with a nephrologist*
- *Our nephrologist group may provide this consultation in patients at lower risk of progression via FAX.*

STEP 1 – Demographics

Patient Name _____
Date of Birth _____
PHN _____
MHSC _____

STEP 2 – Clinical Data

(within 3 months)

eGFR (>25 mL/min) _____
uACR (>3 mg/mmol) _____
Potassium (< 4.8 mmol/L) _____
ACE or ARB Y ☐ N ☐
SGLT-2i Y ☐ N ☐
IF No, why? _____

Serum [K⁺] and eGFR must be
remeasured 4 weeks after:


- Initiation of treatment
- Restarting treatment
- Increase in dose



Thereafter, serum [K⁺] should be **remeasured periodically** and **as needed***

Treatment can be **maintained** in patients with an eGFR ≥15 mL/min/1.73 m². If eGFR falls below 15 mL/min/1.73 m² treatment should be **discontinued**.

Dose adjustments:



STEP 3 FAX TO:

**Seven Oaks Hospital
Nephrologists**

204-940-2329

NEPHROLOGIST REVIEW:

Finerenone Indicated ☐
Finerenone NOT Indicated ☐
Formal consultation requested ☐

Nephrologist

Date